Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma
暂无分享,去创建一个
Ian G. Campbell | Ella R. Thompson | Kylie L. Gorringe | Samantha E. Boyle | E. Thompson | I. Campbell | K. Opeskin | Clint E. Johnson | Ken Opeskin | Yuker Wang | Prue Hill | G. Bruce Mann | C. Johnson | P. Hill | GB Mann | Y. Wang
[1] R. Salunga,et al. Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[2] C. Yamashiro,et al. Extraction and Amplification of DNA From Formalin-Fixed, Paraffin-Embedded Tissues , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[3] J. Minna,et al. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. , 2001, The American journal of pathology.
[4] Tomas W. Fitzgerald,et al. Breaking the waves: improved detection of copy number variation from microarray-based comparative genomic hybridization , 2007, Genome Biology.
[5] J. Thiery,et al. Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.
[6] T. Sørlie,et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer , 2010, Molecular oncology.
[7] M. Ranson,et al. Peptides and small molecules targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for breast cancer. , 2008, Recent patents on anti-cancer drug discovery.
[8] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[9] S. Devries,et al. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. , 2000, Journal of the National Cancer Institute.
[10] I. Bièche,et al. Genetic pathways in the evolution of breast ductal carcinoma in situ , 2002, The Journal of pathology.
[11] A. Ashworth,et al. Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.
[12] T. Karn,et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer , 2008, Breast Cancer Research and Treatment.
[13] Y. Niu,et al. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization , 2009, Journal of Molecular Medicine.
[14] Sean Davis,et al. Molecular Grading of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.
[15] P. O’Connell,et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. , 1998, Journal of the National Cancer Institute.
[16] S. Swain,et al. Ductal carcinoma in situ, complexities and challenges. , 2004, Journal of the National Cancer Institute.
[17] Hugo M. Horlings,et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets , 2009, Oncogene.
[18] S. Tavaré,et al. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.
[19] Jun Yao,et al. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. , 2006, Cancer research.
[20] Kylie L. Gorringe,et al. Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.
[21] Mary E. Edgerton,et al. Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer , 2011, PloS one.
[22] James Ireland,et al. Analysis of molecular inversion probe performance for allele copy number determination , 2007, Genome Biology.
[23] J. Barrett,et al. PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.
[24] M. J. van de Vijver,et al. Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas , 2003, The Journal of pathology.
[25] G. Sauter,et al. Gene amplification in ductal carcinoma in situ of the breast , 2010, Breast Cancer Research and Treatment.
[26] Karla Kerlikowske,et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. , 2007, Cancer cell.
[27] H. Bu,et al. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor. , 2008, Oncology reports.
[28] Li Li,et al. High‐resolution genomic and expression analyses of copy number alterations in breast tumors , 2008, Genes, chromosomes & cancer.
[29] H. Brentani,et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma , 2008, Breast Cancer Research.
[30] J. Reis-Filho,et al. Breast cancer precursors revisited: molecular features and progression pathways , 2010, Histopathology.
[31] E. Petricoin,et al. Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival , 2010, PloS one.
[32] M. Ringnér,et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.
[33] L. Rhodes,et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. , 2011, Journal of molecular endocrinology.
[34] Y. Mo,et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. , 2008, Cancer research.
[35] Karla Kerlikowske,et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. , 2010, Journal of the National Cancer Institute.
[36] P. Spellman,et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays , 2009, BMC Medical Genomics.
[37] Ajay N. Jain,et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.
[38] Jill P. Mesirov,et al. Portraits of breast cancer progression , 2007, BMC Bioinformatics.
[39] Randal L. Croshaw,et al. Somatic mutations to CSMD1 in colorectal adenocarcinomas , 2008, Cancer biology & therapy.
[40] L. Liotta,et al. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. , 1995, Cancer research.
[41] Bjørn Tore Gjertsen,et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.
[42] Mitsutaka Kadota,et al. Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. , 2009, Cancer research.
[43] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[44] S. Lakhani,et al. The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions , 2003, Breast Cancer Research.